These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 25491927)

  • 41. Low-affinity M(2) receptor binding state mediates mouse atrial bradycardia: comparative effects of carbamylcholine and the M(1) receptor agonists sabcomeline and xanomeline.
    Stengel PW; Cohen ML
    J Pharmacol Exp Ther; 2001 Mar; 296(3):818-24. PubMed ID: 11181912
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Enhanced performance of spatial and visual recognition memory tasks by the selective acetylcholinesterase inhibitor E2020 in rhesus monkeys.
    Rupniak NM; Tye SJ; Field MJ
    Psychopharmacology (Berl); 1997 Jun; 131(4):406-10. PubMed ID: 9226744
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Activation of M
    Cadeddu R; Braccagni G; Branca C; van Luik ER; Pittenger C; Thomsen MS; Bortolato M
    Br J Pharmacol; 2024 Sep; 181(17):3064-3081. PubMed ID: 38689378
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Importance and prospects for design of selective muscarinic agonists.
    Jakubík J; Michal P; Machová E; Dolezal V
    Physiol Res; 2008; 57 Suppl 3():S39-S47. PubMed ID: 18481916
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors.
    Shannon HE; Bymaster FP; Calligaro DO; Greenwood B; Mitch CH; Sawyer BD; Ward JS; Wong DT; Olesen PH; Sheardown MJ; Swedberg MD; Suzdak PD; Sauerberg P
    J Pharmacol Exp Ther; 1994 Apr; 269(1):271-81. PubMed ID: 7909557
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 receptor knockout mice.
    Woolley ML; Carter HJ; Gartlon JE; Watson JM; Dawson LA
    Eur J Pharmacol; 2009 Jan; 603(1-3):147-9. PubMed ID: 19111716
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Synthesis and biological evaluation of a novel series of heterobivalent muscarinic ligands based on xanomeline and 1-[3-(4-butylpiperidin-1-yl)propyl]-1,2,3,4-tetrahydroquinolin-2-one (77-LH-28-1).
    Bonifazi A; Yano H; Del Bello F; Farande A; Quaglia W; Petrelli R; Matucci R; Nesi M; Vistoli G; Ferré S; Piergentili A
    J Med Chem; 2014 Nov; 57(21):9065-77. PubMed ID: 25275964
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The muscarinic M1 agonist xanomeline increases soluble amyloid precursor protein release from Chinese hamster ovary-m1 cells.
    Eckols K; Bymaster FP; Mitch CH; Shannon HE; Ward JS; DeLapp NW
    Life Sci; 1995; 57(12):1183-90. PubMed ID: 7674807
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The utility of muscarinic agonists in the treatment of Alzheimer's disease.
    Messer WS
    J Mol Neurosci; 2002; 19(1-2):187-93. PubMed ID: 12212779
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacological evaluation of the long-term effects of xanomeline on the M(1) muscarinic acetylcholine receptor.
    Grant MK; Noetzel MJ; De Lorme KC; Jakubík J; Doležal V; El-Fakahany EE
    PLoS One; 2010 Dec; 5(12):e15722. PubMed ID: 21203415
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sex dimorphisms in the cognitive-enhancing action of the Alzheimer's drug donepezil in aged Rhesus monkeys.
    Buccafusco JJ; Jackson WJ; Stone JD; Terry AV
    Neuropharmacology; 2003 Mar; 44(3):381-9. PubMed ID: 12604096
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Progress toward a high-affinity allosteric enhancer at muscarinic M1 receptors.
    Lazareno S; Popham A; Birdsall NJ
    J Mol Neurosci; 2003; 20(3):363-7. PubMed ID: 14501021
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Xanomeline suppresses excessive pro-inflammatory cytokine responses through neural signal-mediated pathways and improves survival in lethal inflammation.
    Rosas-Ballina M; Valdés-Ferrer SI; Dancho ME; Ochani M; Katz D; Cheng KF; Olofsson PS; Chavan SS; Al-Abed Y; Tracey KJ; Pavlov VA
    Brain Behav Immun; 2015 Feb; 44():19-27. PubMed ID: 25063706
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The effects of novel cholinesterase inhibitors and selective muscarinic receptor agonists in tests of reference and working memory.
    Dawson GR; Iversen SD
    Behav Brain Res; 1993 Nov; 57(2):143-53. PubMed ID: 8117420
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Donepezil: a review of its use in Alzheimer's disease.
    Dooley M; Lamb HM
    Drugs Aging; 2000 Mar; 16(3):199-226. PubMed ID: 10803860
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Two novel 5-HT6 receptor antagonists ameliorate scopolamine-induced memory deficits in the object recognition and object location tasks in Wistar rats.
    de Bruin NM; Prickaerts J; van Loevezijn A; Venhorst J; de Groote L; Houba P; Reneerkens O; Akkerman S; Kruse CG
    Neurobiol Learn Mem; 2011 Sep; 96(2):392-402. PubMed ID: 21757018
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat.
    Stanhope KJ; Mirza NR; Bickerdike MJ; Bright JL; Harrington NR; Hesselink MB; Kennett GA; Lightowler S; Sheardown MJ; Syed R; Upton RL; Wadsworth G; Weiss SM; Wyatt A
    J Pharmacol Exp Ther; 2001 Nov; 299(2):782-92. PubMed ID: 11602695
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Functional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptors.
    Watson J; Brough S; Coldwell MC; Gager T; Ho M; Hunter AJ; Jerman J; Middlemiss DN; Riley GJ; Brown AM
    Br J Pharmacol; 1998 Dec; 125(7):1413-20. PubMed ID: 9884068
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Surface modified nano-lipid drug conjugates of positive allosteric modulators of M1 muscarinic acetylcholine receptor for the treatment of Alzheimer's disease.
    Chintamaneni PK; Krishnamurthy PT; Rao PV; Pindiprolu SS
    Med Hypotheses; 2017 Apr; 101():17-22. PubMed ID: 28351483
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Persistent binding and functional antagonism by xanomeline at the muscarinic M5 receptor.
    Grant MK; El-Fakahany EE
    J Pharmacol Exp Ther; 2005 Oct; 315(1):313-9. PubMed ID: 16002459
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.